PMID- 26372950
OWN - NLM
STAT- MEDLINE
DCOM- 20160914
LR  - 20220310
IS  - 1422-6421 (Electronic)
IS  - 1422-6405 (Linking)
VI  - 200
IP  - 5
DP  - 2015
TI  - Remyelination after Lysophosphatidyl Choline-Induced Demyelination Is Stimulated 
      by Bone Marrow Stromal Cell-Derived Oligoprogenitor Cell Transplantation.
PG  - 300-6
LID - 10.1159/000437350 [doi]
AB  - Bone marrow stromal cells (BMSCs) are a desirable cell source that may be useful 
      for the treatment of neurodegenerative diseases given their capacity to 
      differentiate into various types of cells. The current study aimed to investigate 
      whether oligoprogenitor cell (OPC)-derived BMSCs have therapeutic benefits in an 
      animal model of local demyelination. BMSCs were transdifferentiated into OPCs 
      using a defined culture medium supplemented with a combination of inducers. The 
      differentiation capacity of the BMSCs was evaluated at the end of the induction 
      phase by assessing the expression levels of the glial-specific markers 
      oligodendrocyte transcription factor 2 and O4 surface antigen. Local 
      demyelination was induced in the corpus callosum of adult female rats via direct 
      injection of lysophosphatidylcholine (LPC) followed by engraftment of 
      BMSC-generated OPCs. The rats were divided into sham control, vehicle control, 
      and cell-transplanted groups. The changes in the extent of demyelination and the 
      robustness of the remyelination event were assessed using Luxol Fast Blue 
      staining and immunohistochemical analysis 1 week after LPC injection and 2 weeks 
      after cell transplantation. Consequently, transplantation of OPCs into the 
      demyelinated corpus callosum model resulted in differentiation of the cells into 
      mature oligodendrocytes that were immunopositive for myelin basic protein. 
      Furthermore, OPC transplantation mitigated demyelination and augmented 
      remyelination relative to controls. These findings suggest that BMSC-derived OPCs 
      can be utilized in therapeutic approaches for the management of 
      demyelination-associated diseases such as multiple sclerosis.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Nazm Bojnordi, M
AU  - Nazm Bojnordi M
AD  - Molecular and Cell Biology Research Center, Department of Anatomy and Cell 
      Biology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, 
      Iran.
FAU - Ghasemi, H H
AU  - Ghasemi HH
FAU - Akbari, E
AU  - Akbari E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150916
PL  - Switzerland
TA  - Cells Tissues Organs
JT  - Cells, tissues, organs
JID - 100883360
RN  - 0 (Lysophosphatidylcholines)
SB  - IM
MH  - Animals
MH  - Bone Marrow/metabolism
MH  - Cell Differentiation/*physiology
MH  - Cells, Cultured
MH  - Demyelinating Diseases/chemically induced/*therapy
MH  - Disease Models, Animal
MH  - Lysophosphatidylcholines/toxicity
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
MH  - Myelin Sheath/*metabolism
MH  - Nerve Regeneration/*physiology
MH  - Rats, Sprague-Dawley
EDAT- 2015/09/16 06:00
MHDA- 2016/09/15 06:00
CRDT- 2015/09/16 06:00
PHST- 2015/07/02 00:00 [accepted]
PHST- 2015/09/16 06:00 [entrez]
PHST- 2015/09/16 06:00 [pubmed]
PHST- 2016/09/15 06:00 [medline]
AID - 000437350 [pii]
AID - 10.1159/000437350 [doi]
PST - ppublish
SO  - Cells Tissues Organs. 2015;200(5):300-6. doi: 10.1159/000437350. Epub 2015 Sep 
      16.